Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02239094 · ClinicalTrials.gov registry record · NA
Biosignatures of Latuda for Bipolar Depression
A NA study of Bipolar Depression, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02239094: Completed NA study of Bipolar Depression, sponsored by New York State Psychiatric Institute.
NCT02239094 is a NA study of Bipolar Depression that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 20 participants, below the 215-participant average among 29 other Bipolar Depression trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02239094, a NA study of Bipolar Depression, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The study proposes to conduct a pilot study of biological predictors of lurasidone response in bipolar depression.
Primary Outcome
The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item clinician-administered scale, designed to be particularly sensitive to antidepressant treatment effects in patients with major depression. Nine of the items are based upon patient report, and one is on the rater's observation during the rating interview. MADRS items are rated on a 0-6 continuum (0=no abnormality, 6=severe).
Conditions Studied
Interventions
- DRUG Lurasidone (Latuda)
Study Locations (1)
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-09 |
| Phase | NA |
What the finished NCT02239094 record still lists
NCT02239094 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 215-participant average among 29 other Bipolar Depression trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Bipolar Depression appearing as the primary indexed condition, and to 1 intervention - of which Lurasidone (Latuda) is the first listed.
NCT02239094 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02239094 about?
NCT02239094 is a clinical study titled "Biosignatures of Latuda for Bipolar Depression". The study proposes to conduct a pilot study of biological predictors of lurasidone response in bipolar depression.
What is the current status of trial NCT02239094?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2015-01. Estimated completion is 2016-09.
What conditions does trial NCT02239094 study?
This clinical trial studies the following conditions: Bipolar Depression.
What interventions are being tested in trial NCT02239094?
The interventions under investigation include: Lurasidone (Latuda) (DRUG).
Who is sponsoring clinical trial NCT02239094?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02239094 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02239094's enrollment target sits among peer trials
20 22nd of 29 higher than 3 of 29 other Bipolar Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bipolar Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketogenic Intervention for Bipolar Depression
RECRUITING · NA
-
Deep Brain Stimulation of Treatment-Resistant Bipolar Depression
RECRUITING · NA
-
Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression
ACTIVE NOT RECRUITING · NA
-
Focused Ultrasound Amygdala Neuromodulation
ACTIVE NOT RECRUITING · NA
-
Low Field Magnetic Stimulation in Mood Disorders Using the LFMS Device
COMPLETED · NA
-
Vitamin D Supplementation for Bipolar Depression
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia